- Adial commented on the introduction of H.R. 7091, the Expanding Veterans' Access to Emerging Treatments Act, which would expand research and development of emerging therapies for veterans, including Alcohol Use Disorder.
- The company said the bill supports investigational therapies aligned with an updated federal definition of recovery that includes non-abstinence based treatment options.
- Adial stated that its lead investigational candidate, AD04, is being developed as a genetically targeted, non-abstinence based therapy for Alcohol Use Disorder.
- The company noted the bill has been referred to the House Committee on Veterans' Affairs.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adial Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603240907PRIMZONEFULLFEED9676698) on March 24, 2026, and is solely responsible for the information contained therein.